Placeholder Banner

BIO Comments on FDA Discussion Paper: Distributed Manufacturing and Point-of-Care Manufacturing of Drugs

December 13, 2022

On Tuesday, December 13th, BIO submitted comments in response to a recent FDA discussion paper for stakeholders on distributed manufacturing (DM) and point-of-care (POC) manufacturing. In the comments submitted, BIO commended the FDA on its collaborative approach to addressing unique challenges related to advanced manufacturing and noted that discussion paper provides a timely mechanism to further the harmonization of terminology and concepts around DM and POC. Along with specific feedback on the questions raised by the Agency in the paper, BIO offered several high-level recommendations. For example, it would be beneficial if FDA more clearly conveyed the benefits offered by DM and POC manufacturing while acknowledging the relative risks associated with their introduction. Furthermore, it would be useful if the document recognized and addressed the limitations that manufacturers face in attempting to deploy these technologies in different regions and settings.

Download Full Comments Below
BIO Comments_DM and POC_FDA-2022-N-2316
Discover More
BIO and its members appreciate the opportunity to work with FDA to develop and align on approaches that are robust, practical, and expedite patient focused drug development. To further enhance the Guidance, we believe that a few areas would benefit…
On Wednesday, June 22nd, BIO submitted comments on the FDA’s Quality Metrics (QM) Reporting Program. In the comments submitted, BIO stated appreciation for FDA’s intent to support a general shift toward a risk-based approach to regulation by…
On Wednesday, September 28th, BIO submitted comments to the Food & Drug Administration on the ICH Q2(R2) Guideline: Validation of Analytical Procedures and the ICH Q14 Guideline: Analytical Procedure Development. In addition to a number of…